GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Shiller PE Ratio

Rigel Pharmaceuticals (STU:RI2A) Shiller PE Ratio : (As of Jun. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rigel Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Rigel Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Shiller PE Ratio Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rigel Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Rigel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Shiller PE Ratio falls into.



Rigel Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Rigel Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Rigel Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.046/131.7762*131.7762
=-0.046

Current CPI (Mar. 2024) = 131.7762.

Rigel Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.213 100.560 -0.279
201409 -0.186 100.428 -0.244
201412 -0.203 99.070 -0.270
201503 -0.194 99.621 -0.257
201506 -0.143 100.684 -0.187
201509 -0.071 100.392 -0.093
201512 -0.129 99.792 -0.170
201603 -0.171 100.470 -0.224
201606 -0.134 101.688 -0.174
201609 -0.214 101.861 -0.277
201612 -0.152 101.863 -0.197
201703 -0.122 102.862 -0.156
201706 -0.142 103.349 -0.181
201709 -0.117 104.136 -0.148
201712 -0.152 104.011 -0.193
201803 -0.138 105.290 -0.173
201806 -0.137 106.317 -0.170
201809 -0.120 106.507 -0.148
201812 0.018 105.998 0.022
201903 -0.097 107.251 -0.119
201906 -0.106 108.070 -0.129
201909 -0.064 108.329 -0.078
201912 -0.090 108.420 -0.109
202003 0.118 108.902 0.143
202006 -0.089 108.767 -0.108
202009 -0.068 109.815 -0.082
202012 -0.090 109.897 -0.108
202103 0.185 111.754 0.218
202106 -0.066 114.631 -0.076
202109 -0.102 115.734 -0.116
202112 -0.115 117.630 -0.129
202203 -0.145 121.301 -0.158
202206 -0.076 125.017 -0.080
202209 -0.111 125.227 -0.117
202212 0.009 125.222 0.009
202303 -0.075 127.348 -0.078
202306 -0.037 128.729 -0.038
202309 -0.028 129.860 -0.028
202312 0.009 129.419 0.009
202403 -0.046 131.776 -0.046

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rigel Pharmaceuticals  (STU:RI2A) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Rigel Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines